# Dynamic changes of natural killer cell immunophenotypes and receptors according to the mortality in the intra-abdominal murine sepsis model

**Authors:** Sang Hoon Han, Yeon-Mi Hong, Dayeong Kim, Eun Hwa Lee, Hye Seong

PMC · DOI: 10.1186/s40635-025-00829-6 · 2025-11-19

## TL;DR

This study examines how natural killer cells change in mice with sepsis and finds that their recovery is linked to survival, while persistent suppression is linked to death.

## Contribution

The study identifies dynamic changes in NK cell immunophenotypes and receptors in a murine sepsis model, linking their recovery to survival and suppression to mortality.

## Key findings

- In mice with mid-grade sepsis, natural killer cell activity was initially suppressed but recovered by day 7.
- Recovery was marked by increased activating receptors, decreased inhibitory receptors, and higher granzyme B levels.
- High-grade sepsis was associated with persistent suppression of natural killer cell activity and lethal outcomes.

## Abstract

Sepsis is a life-threatening infectious syndrome that lacks targeted pharmacological therapies and poses major challenges in reducing mortality and long-term complications such as disability and frailty. Early and intensive intervention is critical to improving prognosis and preventing multiorgan dysfunction. However, alternative treatment strategies are urgently needed for patients who do not respond to guideline-based resuscitation, such as those outlined in the Surviving Sepsis Campaign. Natural killer (NK) cells are key effectors of the innate immune system, and their balanced activity may be crucial in preventing the progression of sepsis. Given conflicting evidence on whether NK cell activity (NKA) is protective or harmful, we investigated NKA in a murine model of intra-abdominal sepsis, assessing activating and inhibitory NK receptors (NKRs), as well as NK cell subsets in whole blood, bone marrow, lymph nodes, spleen, and liver.

C57BL/6 mice underwent cecal ligation and puncture (CLP) to induce mid-grade (MGS, 30% 7-day survival) or high-grade sepsis (HGS, 0% 7-day survival), with sham-operated mice as controls. Blood and immune-related organs were collected on days 1, 3, and 7 post-surgery (MGS: days 1, 3, 7; HGS: days 1, 3; Sham: day 7). Flow cytometry was used to analyze CD11b and CD27 expression to define maturation-associated cytolytic and cytokine-producing NK cell phenotypes. CD3⁻NK1.1⁺ NK cells were purified by FACS for RT-PCR of activating (Ly49D, Ly49H) and inhibitory (Ly49C, Ly49G2) NKRs, and ELISA was performed for granzyme B and IFN-γ.

Our experiments consistently showed that in MGS, NKA—initially suppressed—was significantly restored by day 7 after CLP. This recovery was characterized by increased expression of activating NKRs, decreased inhibitory NKRs, expansion of terminally differentiated cytotoxic NK subsets (CD11b+/CD27−), higher total NK cell counts, and elevated granzyme B levels. In contrast, HGS, associated with high lethality, was marked by persistent suppression of NKA.

The sustained impairment of NK cell phenotype is associated with lethal outcomes in sepsis.

The online version contains supplementary material available at 10.1186/s40635-025-00829-6.

## Linked entities

- **Genes:** LY49D (killer cell lectin-like receptor) [NCBI Gene 100034119], Klra8 (killer cell lectin-like receptor, subfamily A, member 8) [NCBI Gene 16639], LY49C (killer cell lectin-like receptor) [NCBI Gene 100033863], Klra7 (killer cell lectin-like receptor, subfamily A, member 7) [NCBI Gene 16638]
- **Proteins:** IFNG (interferon gamma)

## Full-text entities

- **Genes:** Klra4 (killer cell lectin-like receptor, subfamily A, member 4) [NCBI Gene 16635] {aka Chok, Klra32, Klra33, Ly-49d, Ly49d, ly49r<129>}, Klra21 (killer cell lectin-like receptor subfamily A, member 21) [NCBI Gene 93968] {aka Klra-ps1, Ly49H, Ly49u}, Klra7 (killer cell lectin-like receptor, subfamily A, member 7) [NCBI Gene 16638] {aka LGL-1, Ly-49G.1, Ly-49G.2, Ly-49G.3, Ly49G.4, Ly49g}, Gzmb (granzyme B) [NCBI Gene 14939] {aka CCP-1/C11, CCP1, Ctla-1, Ctla1, GZB}, Cd247 (CD247 antigen) [NCBI Gene 12503] {aka 4930549J05Rik, A430104F18Rik, Cd3, Cd3-eta, Cd3-zeta, Cd3h}, Klra3 (killer cell lectin-like receptor, subfamily A, member 3) [NCBI Gene 16634] {aka 5E6, Ly49c, NK-2.1, Nk-2, Nk2, Nk2.1}, Klrb1c (killer cell lectin-like receptor subfamily B member 1C) [NCBI Gene 17059] {aka CD161, Klrb1b, Ly-59, Ly55c, Ly59, NK-RP1}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Cd27 (CD27 antigen) [NCBI Gene 21940] {aka S152, Tnfrsf7, Tp55}, Itgam (integrin alpha M) [NCBI Gene 16409] {aka CD11b/CD18, CR3, CR3A, Cd11b, F730045J24Rik, Ly-40}
- **Diseases:** frailty (MESH:D000073496), intra-abdominal sepsis (MESH:D000082122), MGS (MESH:C548078), infectious syndrome (MESH:D003141), multiorgan dysfunction (MESH:D009102), Sepsis (MESH:D018805), HGS (MESH:D008228)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12630530/full.md

---
Source: https://tomesphere.com/paper/PMC12630530